Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer Inc. (PFE) has completed a Phase 2 study called “A Phase 2, Randomized, Partially Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine Administered in Healthy Toddlers 12 Through 15 Months of Age.” The goal is to see how well a new pneumococcal vaccine protects toddlers and how safe and tolerable it is, a key step to defend against serious childhood infections and to extend Pfizer’s vaccine franchise.

The trial tests a new multivalent pneumococcal conjugate vaccine, code-named PG4, and compares it with Pfizer’s marketed 20-valent pneumococcal conjugate vaccine, Prevnar 20 (20vPnC). PG4 is designed to broaden protection against more strains of pneumococcal bacteria, while Prevnar 20 serves as an active control and helps benchmark safety and immune response in a real-world commercial context.

The study is interventional and randomized, meaning toddlers are assigned by chance to one of several groups. It uses a parallel design with a partially blinded setup, so most participants and study staff do not know which vaccine is given, and the main aim is prevention, not treatment, allowing a cleaner read on vaccine safety and immune response.

Children are split into three groups: a PG4 1-dose arm, a PG4 2-dose arm, and a single-dose Prevnar 20 arm. The PG4 groups differ only in how many injections they receive, while the Prevnar 20 group helps Pfizer gauge if PG4 can match or beat the current standard, which is critical for future approval and commercial positioning in the pediatric market.

The study was first submitted on July 23, 2024, marking the formal start of regulatory tracking and signaling the early clinical push for PG4. The latest update was filed on March 9, 2026, and the status now shows as completed, which means data collection is done and investors can start to look ahead to upcoming readouts and possible conference presentations.

While primary and final completion dates are not detailed here, toddlers participated for about 6 to 8 months depending on dose group. This window covered clinic visits, vaccine administration, and blood draws, and it suggests that immune-response and safety data should be robust enough to support dose and schedule decisions for a potential Phase 3 program.

For investors, the main takeaway is that Pfizer continues to invest in next-generation pneumococcal vaccines, a category that already generates material revenue through Prevnar. A positive Phase 2 outcome for PG4 could extend Pfizer’s lead in pediatric vaccines, protect share against rivals like Merck in pneumococcal disease, and underpin long-term, high-margin recurring sales from national immunization programs.

In the near term, sentiment around PFE could benefit from the perception that its vaccine pipeline is deeper than current earnings suggest, especially as COVID vaccine revenue normalizes. The real share-price impact will depend on how PG4’s safety and immune profile compares with Prevnar 20, but a completed Phase 2 study in toddlers is a meaningful de-risking step for this asset.

The trial is now listed as completed and has been recently updated, and investors can track future data releases and regulatory steps as they appear on the ClinicalTrials portal.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.